Efficacy and safety of 5% imiquimod cream in external genital warts: A 6 month follow-up evaluation;Efficacité et tolérance de l'imiquimod crème 5 % dans le traitement des condylomes acuminés externes: Résultats d'un suivi à 6 mois

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 11 I, 2005, Pages 845-851

  Vexiau, D ^a   Decuypere L ^b   Moyse, D ^b   Aractingi, S ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DYSURIA; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PATIENT ASSESSMENT; POLLAKISURIA; RECURRENT DISEASE; TREATMENT OUTCOME;

EID: 29844453461     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0151-9638(05)79502-8     Document Type: Article

References (26)

1. Chuang TY. Condylomata acuminata (genital warts). An epidemiologic view. J Am Acad Dermatol 1987;16:376-84.
2. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3-8.
3. Chuang TY, Perry HO, Kurland LT, Ilstrup DM. Condyloma acuminatum in Rochester, Minn, 1950-1978. I. Epidemiology and clinical features. Arch Dermatol 1984;120:469-75.
4. CDC. Condyloma acuminatum - United States, 1966-1981. MMWR Morb Mortal Wkly Rep 1983;32:306-8.
5. Bouscarat F, Mahé E, Descamps V. Condylomes externes. Ann Dermatol Veneorol 2002;129:1013-22.
6. Severson J, Evans TY, Lee P, Chan TS, Arany I, Tyring SK. Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy. J Cutan Med Surg 2001;5:43-60.
7. Members of the European Course on HPV Associated Pathology (ECHPV) : von Krogh G, Lacey CJN, Gross G, Barasso R, Schneider A. European guideline for the management of anogenital warts. Int J STD AIDS 2001;12 (S3):40-7.
8. Wiley DJ, Douglas J, Beutner K, Cox T, Fife K, Mscicki AB, et al. External genital warts: Diagnosis, treatment and prevention. CID 2002:35(S2):S210-S224.
9. Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, et al. Self-administered topical 5 % imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 1998;134:25-30.
10. Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230-9.
11. n. Garland SM, Sellors JW, Wikstrom A, Petersen CS, Aranda C, Aractingi S, et al. Imiquimod 5 % cream is a safe and effective self-applied treatment for anogenital warts - results of an open label, multicentre Phase IIIB trial. Int J STD AIDS 2001;12:722-9.
12. Vilata JJ, Badia X, and the ESCRIM group. Effectiveness, satisfaction and compliance with imiquimod in the treatment of external anogenital warts. Int J STD AIDS 2003;14:11-7.
13. Sauder DN, Skinner RB, Fox TL, Owens ML. Topical Imiquimod 5 % cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003;3:124-8.
14. Buck HW, Fortier M, Knudsen J, Paavonen J. Imiquimod 5 % cream in the treatment of anogenital warts in female patients. Int J Gynecol and obstetrics 2002;77:231-8.
15. Fife KH, Ferenczy A, Douglas JM, Brown DR, Smith M, Owens ML and the HPV study group. Treatment of external genital warts in men using 5 % imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis 2001;28:226-31.
16. Maw RD, Kinhorn GR, Bowman CA, Goh BT, Nayagam AT, Nathan M. Imiquimod 5 % cream is an acceptable treatment option for external anogenital warts in uncircumcised males. J EADV 2002;16:58-62.
17. Gollnick H, Barasso R, Jappe U, Ward K, Eul A, Carey-Yard M, et al. Safety and efficacy of imiquimod 5 % cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001;12:22-8.
18. Kraus SJ, Stone KM. Management of genital infection caused by human papillomavirus. Rev Infect Dis 1990:12 Suppl 6:S620-32.
19. Stone KM, Becker TM, Hadgu A, Kraus SJ. Treatment of external genital warts: a randomized clinical trial comparing podophyllin, cryotherapy, and electrodessication. Genitourin Med 1990;66:16-9.
20. Gross G, Von Krogh G. Therapy of anogenital HPV-induced lesions. Clin Dermatol 1997;15:457-70.
21. Kirby P, Dunne A, King DH, Corey L. Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990;88:465-9.
22. Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr. A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991;77:735-9.
23. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135-41.
24. Tyring SK, Arany I, Stanley MA, Tomai MA, Miller RL, Smith MH, et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. Infect Dis 1998;178:551-5.
25. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43:S6-11.
26. Petersen CS, Munkvad S, Christiansen CB. CO2 laser eradication of recalcitrant condyloma acuminatum does not influence T-lymphocyte subsets. Acta Derm Venereol 1998;78:389.